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Edited by Michael R. BubbAbstract Macrophages undergo apoptosis as a mechanism of
regulating their activation and the inﬂammatory reaction. Mac-
rophages express the Corticotropin-Releasing Factor Receptor-2
(CRFR2) the endogenous agonists of which, the urocortins, are
also present at the site of inﬂammation. We have found that uro-
cortins induced macrophage apoptosis in a dose- and time-depen-
dent manner via CRFR2. In contrast to lipopolysaccharide
(LPS)-induced apoptosis, the pro-apoptosis pathway activated
by urocortins involved the pro-apoptotic Bax and Bad proteins
and not nitric oxide, JNK and p38MAPK characteristic of
LPS. In conclusion, our data suggest that endogenous CRFR2 li-
gands exert an anti-inﬂammatory eﬀect via induction of macro-
phage apoptosis.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Following their activation, macrophages undergo apoptosis
as a mechanism to contain inﬂammation [1]. Bacterial lipo-
polysaccharide (LPS) activates macrophages and promotes
their apoptosis via induction of the nitric oxide NO pathway
[2,3].
The corticotropin-releasing factor (CRF) family of peptides
and their receptors are expressed in neural and non-neural cells
including immune cells [4,5]. Urocortin 1 (UCN1), a member
of the CRF family, is detected in lymphoid organs including
spleen and thymus, the gastro-intestinal tract and heart [6,7]
while Urocortin 2 (UCN2) [8] and Urocortin 3 (UCN3) [9]
are mainly expressed in skin and muscle. Urocortins utilize
two diﬀerent receptors, CRFR1 and CRFR2 [10,11]. UCN1
has high aﬃnity towards CRFR2 but it also binds strongly
to CRFR1, while UCN2 and UCN3 are exclusive ligands of
CRFR2 [8,9].
Several published reports suggest that urocortins may play
an anti-inﬂammatory role. Indeed, in gastric biopsies of
patients with Helicobacter pylori-induced gastritis, UCN1 is*Corresponding authors. Fax: +30 2810 394581.
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doi:10.1016/j.febslet.2005.06.057signiﬁcantly elevated during the stage of eradication of H. py-
lori and the amelioration of the inﬂammatory response while it
fails to do so in non-responders [12]. Furthermore, UCN1
tested in a systemic inﬂammation model appears to exert a
direct eﬀect on the cascade of events taking place in inﬂamma-
tion suppressing LPS-induced TNF-a production indepen-
dently of corticosterone [13]. UCN1 also suppresses skin
edema induced by thermal injury [14]. It thus appears that uro-
cortins may act as endogenous anti-inﬂammatory agents. Aim
of this work was to test the hypothesis that the anti-inﬂamma-
tory eﬀect of urocortins involves induction of macrophage
apoptosis.2. Materials and methods
2.1. Reagents and antibodies
UCN1, Escherichia coli-derived LPS (serotype 0111:B4), a-helical
CRF[9–41], propidium iodide were purchased from Sigma Chemicals
Co. (St. Louis, MO) and 7-amino-actinomycinD (7-AAD) was pro-
vided by ICN Biomedicals, Inc. (Costa Mesa, CA). UCN2 and anti-
sauvagine30 were chemically synthesized. Thermoscript RT and
Platinum Taq polymerase were purchased from Invitrogen (NY,
NY), anti-Bax from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA), anti-Bad from Cell Signalling Technology Inc. (Beverly, MA)
and anti-actin from Chemicon (Temecula, CA). All other chemicals
and reagents were obtained from Sigma, if not stated otherwise.2.2. RAW 264.7 cell culture
RAW 264.7 cells (derived from ATCC) were cultured in Dulbeccos
modiﬁed Eagles medium supplemented with 10% fetal calf serum
(FCS), 10 mM L-glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomy-
cin (all purchased from Invitrogen), at 5% CO2 and 37 C. Cells were
plated in 25 cm2 ﬂasks at a concentration of 4 · 105/ml and growth
medium was replaced with DMEM that does not contain FCS 12 h
prior to stimulation. Cells were incubated with LPS plus/minus the
speciﬁed neuropeptides for 24 h. 7AAD staining or pro-apoptotic pro-
tein expression measured apoptosis. In the experiments where inhibi-
tors were used, cells were treated with the inhibitor 1 h prior to
stimulation with each neuropeptide. Parallel control cells treated only
with the diluent were collected at the same time points.2.3. Isolation and stimulation of thioglycollate-elicited macrophages
A 4% thioglycollate solution was prepared and autoclaved 2 days
prior to administration. 1.5 ml of the thioglycollate solution was in-
jected intraperitoneally in C57BL/6 mice and peritoneal macrophages
were isolated by lavage of the peritoneal cavity with Dulbeccos mod-
iﬁed medium [15]. Cells were then cultured in DMEM supplemented
with 10% FCS, 10 mM L-glutamine, 100 U/ml penicillin, 0.1 mg/ml
streptomycin (Gibco).blished by Elsevier B.V. All rights reserved.
4260 C. Tsatsanis et al. / FEBS Letters 579 (2005) 4259–42642.4. Quantitation of nucleosome fragmentation
Cells were plated in 96-well plates at an initial concentration of
10000 cells per well for 24 h. Apoptosis was measured by direct deter-
mination of nucleosomal DNA fragmentation with the ‘‘cell death
detection’’ ELISA plus kit (Cat No. 1 774 425, Boehringer Mannheim
GmbH, Mannheim, Germany). Brieﬂy, cells were harvested and lysed
according to the manufacturers protocol. The mono- and oligo-nucle-
osomes contained in cell lysates were determined using an anti-histone-
biotin antibody, which binds to histones and reacts with single- and
double-stranded DNA. Data were expressed in photometric units.
Each unit corresponds to approximately 12500 apoptotic cells. The
concentration of the nucleosomes was determined photometrically
using 2,2 0-azino-di[3-ethylbenzthiazolin-sulfonate] as substrate for the
biotin present on the antibody. The optical density was read on a
Dynatech MicroElisa Reader (Chantilly, VA) at 405 nm. Each experi-
ment was repeated three times and each sample in triplicate.
2.5. Quantitation of apoptotic cells
The APOPercentage Apoptosis Assay (Biocolor Ltd., Belfast, N.
Ireland) uses a dye that stains red the apoptotic cells undergoing the
membrane ﬂip-ﬂop event when phosphatidylserine is translocated to
the outer leaﬂet. Apoptosis was quantiﬁed by measuring the dye incor-
porated in apoptotic cells following cell lysis, at 550 nm (reference ﬁlter
620 nm) using a color ﬁlter microplate colorimeter (Dynatech Mic-
roElisa reader Chantilly, VA) as previously described [16,17]. Each
sample was measured in triplicate and each experiment was repeated
three times.
2.6. Flow cytometric analysis of apoptotic cells
Cells were treated in 6-well plates as described above and harvested
in culture medium containing 7-AAD. Following 15-min incubation,
cells were washed in cold PBS and re-suspended in PBS containing
propidium iodide (PI) (1 lg/ml) to detect both necrotic and late apop-
totic cells that were excluded from the analysis. Cells were visualized
and analyzed on a ﬂow cytometer (Epics Elite Coulter, UK). The per-
centage of 7AAD positive/PI negative cells that represent apoptotic
population was compared to live cells that were 7AAD negative/PI
negative.
2.7. RT-PCR
Primers for actin were sense, 5 0-TCA GAA GAA CTC CTA TGT
GG-3 0; antisense, 5 0-TCT CTT TGA TGT CAC GCA CG-3 0, giving
a 499 bp product. Primers for CRFR2 were: 5
0-CCGGAATGCCTA-
CAGAGAGT-3 0 and 5 0-AGGTGGTGATGAGGTTCCAG-3 0 giving
a 250 bp product. Total cellular RNA was isolated using Trizol reagent
(Invitrogen). Following reverse transcription, 1 ll of the cDNA prod-
uct was ampliﬁed by PCR, at 33 cycles, annealing to temperature of
55 C. 10 ll of the ampliﬁed products were separated on a 3% agarose
gel and visualized by ethidium bromide staining using the BioRad
Molecular Analyst System.
2.8. Western blot analysis
Cell lysates were electrophoresed through a 12% SDS–polyacryl-
amide gel, then proteins were transferred to nitrocellulose membranes,
which were processed according to standard Western blotting proce-
dures, as previously described [16].
2.9. Statistical analysis
Apoptosis data are presented as optical density (OD) or as normal-
ized ratios to parallel controls or actin content. For statistical evalua-
tion analysis of variance, post hoc comparisons of means followed by
the Fishers least signiﬁcance diﬀerence test were used. For data ex-
pressed as percent changes the non-parametric Kruskal–Wallis test
for several independent samples was used.Fig. 1. UCN1 and UCN2 promoted Raw264.7 macrophage apoptosis
(nucleosomal fragmentation data). (A) Dose–response of UCN1 and
UCN2-induced apoptosis. (B) UCN1 or UCN2 (109 M)-induced
apoptosis was measured at diﬀerent time points. (C) Raw264.7 cells
were treated with UCN1 or UCN2 at 107 M and apoptosis was
measured at diﬀerent time points. Results represent the average of
three independent experiments where each sample was tested in
triplicate. \P < 0.05, \\P < 0.01 or \\\P < 0.001 denote statistically
signiﬁcant diﬀerences compared to parallel controls.3. Results
3.1. Urocortins promoted macrophage apoptosis
Raw264.7 cells were treated with increasing concentrations
of UCN1 or UCN2 and apoptosis was quantiﬁed by measur-
ing nucleosomal fragmentation. Apoptosis was presented asratio 1:1 between control and treated cells. Control cells were
exposed to the diluent only, for the same period as treated
cells. Basal apoptosis was assigned as 100%. UCN1 and
UCN2 induced apoptosis reaching a peak between 108 and
1010 M (Fig. 1A). Subsequently, cells were exposed to
UCN1 or UCN2 at 109 M and apoptosis was measured at
several time points. UCN1 and UCN2 induced apoptosis,
which became detectable at 3 h reaching a peak at 24 h
(Fig. 1B). It should be noted that modest changes of macro-
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the remaining functional macrophages tend to clear apoptotic
neighbors by phagocytosis not allowing them to accumulate in
the medium hiding net apoptosis. No eﬀect on apoptosis was
detectable at higher than 107 M concentrations of UCN1 or
UCN2. To conﬁrm this lack of eﬀect and to rule out eﬀect at
other time points, cells were treated with UCN1 or UCN2 at
107 or 106 M at apoptosis was measured at multiple time
points. No eﬀect was observed at any of the time points tested
(Fig. 1C and data not shown). Flow cytometry following stain-
ing with 7-AAD conﬁrmed the nucleosomal fragmentation
data (Fig. 2A and B). LPS induced a similar to urocortins de-
gree of macrophage apoptosis, supporting the signiﬁcant role
of the latter.
In thioglycollate-elicited primary mouse macrophages
(TEPM), UCN1 and UCN2 induced a similar degree of apop-
tosis, which peaked at 6 h (Fig. 3A). It should be noted that the
observed earlier apoptosis in primary cultures was expected be-
cause of the well-known higher sensitivity of primary cells
compared to cell lines. Finally, in agreement with the cell line
data, exposure of primary macrophages to UCN1 or UCN2 at
higher concentrations, i.e. 107 or 106 M did not show any
signiﬁcant eﬀect on apoptosis (Fig. 3B and data not shown).Fig. 2. UCN1 and UCN2 promoted Raw264.7 macrophage apoptosis
(Flow cytometry data). Raw264.7 cells were treated with the CRFR2
agonists UCN1 or UCN2 (109 M), or LPS (10 lg/ml) and apoptotic
cells were stained with 7-AAD and visualized by Flow Cytometry. (A)
Apoptotic cells are shown as percentage of the total population. (B)
Representative raw data of three independent experiments.
Fig. 3. UCN1 and UCN2 promoted thioglycollate-elicited peritoneal
macrophage (TEPM) apoptosis. TEPMs were exposed to UCN1
(109 M), UCN2 (109 M) or LPS (10 lg/ml) (A) or UCN1 (107 M)
or UCN2 (107 M) (B) for diﬀerent time periods. Results represent the
average of three independent experiments where each sample was
tested in triplicate. \P < 0.05 denotes statistically signiﬁcant diﬀerences
compared to parallel controls.3.2. Urocortins induced macrophage apoptosis via CRFR2
Raw264.7 and TEPM cells express the CRFR1 and CRFR2
receptors (Fig. 4A and B). Speciﬁc CRFR1 and CRFR2 recep-
tors antagonists were used to assess their role in UCN-induced
apoptosis using the inversion of phosphatidylserine located at
cell membranes (Apo-percentage assay), a method detecting
apoptosis at a much earlier stage. Exposure of Raw264.7 or
TEPM cells to CRFR2 speciﬁc antagonist anti-sauvagine30
at 107 M completely abolished the pro-apoptotic eﬀect of
UCN1 and UCN2 (Fig. 4C and D). Exposure to CRFR1
antagonist a-helical CRF[9-41] (ah), at 107 M had no eﬀect
on the apoptosis induced by UCN1 (Fig. 4C and D) suggesting
that the pro-apoptotic eﬀect is mediated solely by CRFR2.
UCN1 exhibits high aﬃnity to CRFR2 and 10 times lower
aﬃnity to CRFR1, while UCN2 is a selective CRFR2 agonist
which can bind to CRFR1 only at very high concentrations
(IC50 350 nM) [18]. We, therefore, hypothesized that the pro-
apoptotic eﬀect observed at 109 M of the neuropeptides
may be masked at higher concentrations through their binding
on both CRF receptors. Raw264.7 cells and TEPM were trea-
ted with UCN1 or UCN2 at 107M together with anti-sauva-
gine30 or ahCRF[9–41] at 5 · 106 M, which may unmask
such eﬀect. No statistically signiﬁcant diﬀerence on apoptosis
was observed (Fig. 5).
Fig. 4. The pro-apoptotic eﬀect of UCN1 and UCN2 was mediated by CRFR2. (A) Expression of CRFR1 and CRFR2 in Raw264.7 macrophages
(A) and TEPM (B) as detected by RT-PCR. Raw264.7 cells (C) or TEPMs (D) were treated with vehicle (control), UCN1 or UCN2 (109 M) for 24 h
in the presence or absence anti-sauvagine30 (asvg-30) or a-helical CRF[9–41] (ah). Apoptosis was detected by measuring the inversion of membrane
phosphatidyl-serine (Apop-percentage assay). \P < 0.05 or \\P < 0.01 denote statistically signiﬁcant diﬀerences compared to parallel controls.
#P < 0.05 compared to UCN1 or UCN2 treated cells, respectively.
Fig. 5. Inhibition of CRFR1 or CRFR2 signals did not alter macrophage apoptosis in the presence of high concentrations of UCN1 or UCN2.
Raw264.7 cells (A,B) or TEPMs (C,D) were treated with UCN1 or UCN2 at 107 M in the presence of ahCRF[9–41] or asvg-30 at 106 M and
apoptosis was measured at diﬀerent time points. No statistically signiﬁcant diﬀerence was observed.
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Fig. 7. In contrast to LPS, CRFR2 signals did not aﬀect p38MAPK or
JNK. Raw264.7 cells were treated with UCN1 (109 M), UCN2
(109 M) or LPS (10 lg/ml) for 10 min and the phosphorylated form of
p38MAPK (A) or JNK (B) was measured by Western blot analysis.
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diﬀerent from that of LPS
Raw264.7 cells were treated with UCN1 for diﬀerent time
periods and cells were lysed to detect expression of pro-apop-
totic molecules. We found that UCN1, and to a greater extent
UCN2 induced Bax expression (2.4 and 3.2-fold, respectively)
while LPS induces Bax but at lower levels than urocortins (1.5-
fold). The eﬀect became evident at 4 h following treatment
(Fig. 6A) and Bax remained at high levels 12 h following stim-
ulation. Both LPS and CRFR2 signals induced Bad in
Raw264.7 cells, being 4.8-fold for UCN1, 5.3-fold for UCN2
and 5.5-fold for LPS (Fig. 6B). Thus, induction of Bad con-
ﬁrmed the involvement of pro-apoptotic Bcl2-related proteins
in CRFR2-induced apoptosis and appears to be a common
pathway activated by UCN1, UCN2 and LPS.
LPS-induced apoptosis of Raw264.7 macrophages requires
activation of JNK and p38MAPK. CRFR2 signals had no ef-
fect on JNK or p38MAPK phosphorylation while LPS, which
induced their activation (Fig. 7A and B). LPS-induced apopto-
sis in macrophages is tightly associated to NO production
[1,3,19]. CRFR2 signals did not aﬀect NO
 production at
any concentration or time point (data not shown).Results are representative of three independent experiments.4. Discussion
CRF is a paracrine modulator of inﬂammation. It exerts a
direct eﬀect on macrophages augmenting their production of
pro-inﬂammatory cytokines [15,20]. CRF and UCN1 are de-
tected at the site of inﬂammation in humans [21,22] although
the role of urocortins is unclear. Evidence suggests that uro-
cortins at inﬂammation sites may counteract the pro-inﬂam-
matory eﬀects of CRF [14,23]. Indeed, UCN1 present in the
mucosa of patients suﬀering from H. pylori-induced gastritis
increases during the process of microbe eradication and the
amelioration of inﬂammation while in patients resistant to
treatment its levels remain low [12]. In the present study, weFig. 6. CRFR2 signals activated Bax and Bad. Raw264.7 cells were
treated for 4 h with vehicle (control), UCN1 (109 M), UCN2
(109 M) or LPS (10 lg/ml) and the expression levels of Bax (A) or
Bad (B) was estimated by Western blot. Results are representative of
three independent experiments.propose that urocortins may act as paracrine anti-inﬂamma-
tion agents by accelerating macrophage apoptosis. CRFR1 sig-
nals have been associated with anti-apoptotic or pro-apoptotic
actions in several cell types [16,24]. This is the ﬁrst report asso-
ciating CRFR2 signals to apoptosis. We present evidence that
although both CRF receptors, the CRFR1 and CRFR2 are ex-
pressed in primary macrophages and in RAW264.7 cells the
pro-apoptotic eﬀect of urocortins is mediated only by the
CRFR2 receptors.
The pro-apoptotic eﬀect of urocortins was detectable only at
low concentrations ranging (1010–108 M). Indeed, we did
not observe any signiﬁcant pro- or anti-apoptotic eﬀect of
urocortins at higher concentrations suggesting that their pro-
apoptotic action takes places in a limited window of concen-
trations, which may reﬂect tissue-speciﬁcity based on CRF
receptor distribution. Blocking one or the other of CRF recep-
tors did not unmask any pro- or anti-apoptotic eﬀect suggest-
ing that in macrophages UCN1 aﬀects apoptosis only via
CRFR2. We thus hypothesize that at higher concentrations
urocortins may either induce activation of diﬀerent signaling
molecules that do not aﬀect macrophage homeostasis or bind
to diﬀerent sites of the CRF receptors resulting in altered intra-
cellular signals and biological eﬀects.
Our data also suggest that in macrophages, activation of the
CRFR2 receptor induces apoptosis via the pro-apoptotic pro-
teins Bax and Bad without aﬀecting p38MAPK, JNK or the
production of NO characteristics of LPS-induced apoptosis.
Thus, it appears that urocortins promote macrophage apopto-
sis via a direct eﬀect on pro-apoptotic Bcl2-related proteins in
contrast to LPS that utilizes an indirect pathway. Indeed,
CRFR2-induced apoptosis appears to be faster than that trig-
gered by LPS and comparable in magnitude.
In conclusion, our data suggest that urocortins, the endoge-
nous ligands of the CRFR2 receptor, play an anti-inﬂamma-
tory role via their pro-apoptotic eﬀect on macrophages via a
diﬀerent to LPS signaling pathway.
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